Incyte Corp. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
EUR1.02 |
Market Cap |
EUR16.33 B |
Shares Outstanding |
212.58 M |
Public Float |
142.29 M |
Incyte Corp. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1.17 |
Market Cap |
$18.29 B |
Shares Outstanding |
214.44 M |
Public Float |
212.39 M |
Address |
1801 Augustine Cut-Off Wilmington Delaware 19803 United States |
Employees | - |
Website | http://www.incyte.com |
Updated | 07/08/2019 |
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. |